SchizophreniaNCT05345977
eMotiph: E-mental Health Solution for Patients With Schizophrenia
A study testing eMotiph in people with Schizophrenia, run by Grupo Pulso at 1 site in Spain.
Trial summary
Although the main objective of current schizophrenia intervention programs is the reduction of symptoms, its rates are around 36%, and recovery rates are 16.5%. Between 30 and 50% of people with schizophrenia obtain little benefit with conventional therapy. They are considered resistant to treatment. Read more about this study
- Who is it for?
- Ages 18 to 55 years
- Conditions the study is for
- Schizophrenia
- What is being tested?
- eMotiph
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 7 participants
- Where
- 1 siteSpain
- Study dates
- 1 Jun 2021to 28 Feb 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Age between 18-55 years old.
- Diagnosis of schizophrenia following the Diagnostic and Statistical Manual of Mental Disorders-5 criteria.
- Meet criteria for treatment-resistant schizophrenia.
- Used to information and communication technology and with the physical capability to use them.
Who cannot join
- Meet criteria for remission according to the Remission of Schizophrenia Working Group (Andreasen et al., 2005).
- The presence of delusions mainly related to their therapists or with new technologies.
- Hearing, vision or motor impairment that makes it impossible to operate a smartphone.
- Intellectual Developmental Disability.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: eMotiph: Smart and Innovative E-mental Health Solution to Manage Patients With Schizophrenia
Although the main objective of current schizophrenia intervention programs is the reduction of symptoms, its rates are around 36%, and recovery rates are 16.5%. Between 30 and 50% of people with schizophrenia obtain little benefit with conventional therapy. They are considered resistant to treatment. Therefore, the development of innovative evidence-based interventions adjunctive to pharmacological and psychological treatment are necessary for improving results in patients with treatment-resistant schizophrenia (TRS). Studies with digital solutions have shown feasibility, acceptability and even preliminary efficacy data. But no earlier published study has focused on TRS.
The eMOTIPH is an innovative solution addressed to TRS and born from the outcomes of the previous study eMOTIPH Part 1 (study of beliefs, needs, and limitations associated with current intervention in TRS patients).
Read the detailed description
A prospective non-randomised feasibility trial will be performed. People with a diagnosis of treatment-resistant schizophrenia and their informal caregivers will test the digital mental health solution eMOTIPH for 6 months. Psychiatric treatment and psychological intervention (based on the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders; Farchione et al., 2012) will be delivered to patients.
The aim of the study is to evaluate the feasibility, acceptability, usability, satisfaction and perceived quality of life after using the eMOTIPH digital solution.
- Conditions
- Schizophrenia
- Being tested
- eMotiph
- Keywords
- mHealth, Treatment resistent schizophrenia
- Medical subject headings
- Schizophrenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
eMotiphDevice
Mobile application for patients with schizophrenia.
| Study group | Role | What they receive |
|---|---|---|
| Unified Protocol | Experimental | The psychotherapy Unified Protocol for Transdiagnostic Treatment of Emotional Disorders. Receives: Device: eMotiph |
What is being measured
The primary outcome is the main question the study is designed to answer.
Technology Acceptance Model Scale (TAM)
Degree of acceptance of the digital solution and the intervention delivered. The scale provides scores in 8 dimensions: Perceived Usefulness (score ranges from 5 to 35), Perceived Ease of Use (score ranges from 6 to 42), Attitude (score ranges from 2 to 14), Facilitators (score ranges from 4 to 28), Barriers (score ranges from 2 to 14), Subjective Norm (score ranges from 3 to 21), Intention to Use (score ranges from 1 to 7) and Habits (score ranges from 2 to 14). As much the response trend is located in the positive pole for most of the items, higher acceptability.
Measured: Data will be collected immediately after the intervention.
User experience questionnaire
A questionnaire ad hoc will be created where the degree of usability and lived experience after using the digital solution will be measured. This scale has not cut off points. Higher values mean higher usability.
Measured: Data will be collected immediately after the intervention
Client Satisfaction Questionnaire (CSQ-8)
The opinions and conclusions about the digital solution delivered will be asked. The scale has not cut off points. Higher values mean higher satisfaction.
Measured: Data will be collected immediately after the intervention
Secondary outcomes (27)
Positive and Negative Syndrome Scale (PANSS)
Positive, negative and general symptoms of schizophrenia will be assessed. There are not cut off points, direct scores are converted to percentiles. Higher values mean higher presence of positive, negative and general symptoms.
Measured: Change from Baseline Positive and Negative Syndrome Scale at 6 months.
Calgary Depresion Scale for Schizophrenia (CDS)
The level of depression severity in schizophrenia will be assessed. Cut off points: 0-5, no depression; 6-27, depression.
Measured: Change from Baseline Calgary Depresion Scale for Schizophrenia at 6 months.
Beck Anxiety Inventory (BAI)
The level of anxiety will be assessed. The score range is 0-63. A total score of 0-7 is considered minimal range, 8-15 is mild, 16-25 is moderate, and 26-63 is severe.
Measured: Change from Baseline Beck Anxiety Inventory at 6 months.
Clinical Global Impression (CGI)
The severity of positive, negative, depressive and cognitive symptoms and the overall severity of the disorder will be evaluated. The scale is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. A higher score indicates a higher severity level.
Measured: Change from Baseline Clinical Global Impression at 6 months.
NEO Five-Factor Inventory
Measurement of five personality traits: five factors are named Neuroticism (N), Extraversion (E), Openness. Higher scores indicates higher presence of the trait.
(O), Agreeableness (A), and Conscientiousness (C).
Measured: Change from Baseline NEO Five-Factor Inventory at 6 months.
Toronto Alexithymia Scale (TAS)
Measurement of alexithymia personality trait. Scoring range: 20-100 (higher scores indicate greater impairment).
Measured: Change from Baseline Toronto Alexithymia Scale at 6 months.
Global Assessment Functioning (GAF)
The overall functioning of the patient will be evaluated. The score is between 0-100, where lower scores indicate psychosocial problems that make life difficult for the person under evaluation.
Measured: Change from Baseline Global Assessment Functioning at 6 months.
Personal and Social Performance scale (PSP)
The specific functioning in 4 main areas will be evaluated. The final score ranges from 100 to 0, where from 100 to 70 points, the ratings refer only to mild difficulties, from 70 to 31 to manifest disabilities of various degrees, and under 30 points, the person's functioning is so poor that intensive support or supervision is needed
Measured: Change from Baseline Personal and Social Performance scale at 6 months.
EuroQuol-VAS (EQ-VAS)
Measurement of quality of life according to the patient's perception. It is a 0-100 scale where respondents indicate their overall health status. A higher score indicates higher perceived health.
Measured: Change from Baseline EQ-VAS at 6 months.
Boston University Empowerment Scale (BUES)
Measurement of the personal construct of empowerment. The BUES is a 28-item self-report questionnaire which consists of five factors: self-efficacy and self-esteem, power and powerlessness, community activism, righteous anger, and optimism toward and control over the future. Possible scores range from 1 to 4, with higher scores indicating more empowerment.
Measured: Change from Baseline Boston University Empowerment Scale at 6 months.
Questionnaire about the Process of Recovery
Measurement of patient's viewpoint about recovery from psychosis. The QPR is a 15-item self-report questionnaire scored on a 4-point scale (0= disagree strongly, 4=agree strongly). Higher scores are indicative of recovery.
Measured: Change from Baseline Questionnaire about the Process of Recovery at 6 months.
Visual numerical scale of recovery
Subjective measurement of recovery. This scale ranges from 0 to 10, and higher scores are indicative of recovery.
Measured: Change from Baseline Visual numerical scale of recovery at 6 months.
Psychotic Symptom Rating Scales-hallucinations (PSYRATS-H)
Measurement of severity of each hallucination's dimensions. PSYRATS-H is comprised of 11 items on specific dimensions of hallucinations, with each item being rated from 0 (absent) to 4 (severe). The total score ranges from 2 to 44, with higher scores indicating more severe symptoms.
Measured: Change from Baseline Psychotic Symptom Rating Scales at 6 months.
Peters Delusions Inventory (PDI)
Assessment of delusional symptoms. The PDI is a 21-item questionnaire. Total score is the sum of positive responses on each item, giving a maximum score of 21 points. Likewise, for each one of the items, there are three subscales that measure degree of conviction, preoccupa- tion, and distress The higher the score, the greater the delusional symptoms is.
Measured: Change from Baseline Peters Delusions Inventory at 6 months.
Scale Unawareness of Mental Disorders (SUMD)
Assessment of insight into illness. The scale consists of 3 general items: awareness of mental disorder, awareness of the effects of medication and awareness of the social consequences of the disorder; and of 17 items related to specific symptoms, which make up two subscales: awareness and attribution. Higher scores indicate a lower level of disorder awareness or more incorrect attribution (worse awareness).
Measured: Change from Baseline Scale Unawareness of Mental Disorders at 6 months.
Beck Cognitive Insight Scale
Assessment of insight into cognitive processes involved in anomalous experiences and misinterpretations. The BCIS is a 15-item self-report questionnaire scored on a 4-point scale (0= do not agree at all, 3= agree completely). It is comprised of two subscales, self-reflectiveness and self-certainty, and a composite Reflectiveness-Certainty Index score. The higher this index score, the greater the cognitive insight is.
Measured: Change from Baseline Beck Cognitive Insight Scale at 6 months.
Overall Depression Severity and Impairment Scale (ODSIS)
The level of depression severity will be assessed. ODSIS is a 5-item self-report questionnaire and is scored on a Likert-type scale ranging from 0 to 4. Higher scores indicate greater severity and functional interference associated with depression.
Measured: Data will be collected at baseline, throughout the Unified Protocol sessions and immediately after the intervention.
Overall Anxiety Severity and Impairment Scale (OASIS)
The level of anxiety severity will be assessed. OASIS is a 5-item self-report questionnaire and is scored on a Likert-type scale ranging from 0 to 4. Higher scores indicate greater anxiety-related severity and impairment.
Measured: Data will be collected at baseline, throughout the Unified Protocol sessions and immediately after the intervention.
Baron Cohen's Face Test
Measurement of capacity to recognise basic and complex emotions in faces. consists of 20-items showing pictures of an actress displaying an emotion. Higher scores indicate a greater capacity for recognizing emotions.
Measured: Data will be collected at the baseline and immediately after the intervention.
Emotion Regulation Questionnaire (ERQ)
Measurement of the tendency to regulate emotions. The ERQ is a self-report questionnaire and is scored on a Likert-type scale, ranging from 1 (strongly disagree) to 7 (strongly agree). It is comprised of two subscales, cognitive reappraisal and expressive suppression. Higher scores indicate higher usage of the strategies.
Measured: Data will be collected at the baseline and immediately after the intervention.
Difficulties in Emotion Regulation Scale (DERS)
Measurement of emotional regulation's dimensions. The DERS is a 28-item self-report questionnaire and is scored on a Likert-type scale, ranging from 1 (almost never) to 5 (almost always). It is comprised of five subscales (inattention, confusion, rejection, interference, lack of control) and a total score. Higher scores indicate higher difficulties in emotion regulation.
Measured: Data will be collected at the baseline and immediately after the intervention.
Five Facet Mindfulness Questionnaire (FFMQ)
Assessment of mindfulness' facets. The FFMQ is a 39-item self-report measure and is scored on a Likert-type scale, ranging from 1 (never) to 5 (very often). It is comprised of five subscales: Observing, Describing, Acting with Awareness, Nonjudging of Inner Experience, and Nonreactivity to Inner Experience. Higher scores represent higher subscale levels of mindfulness.
Measured: Data will be collected at the baseline and immediately after the intervention.
Involuntary Autobiographical Memory Inventory (IAMI)
Measurement of the frequency of involuntary autobiographical memories and involuntary future thoughts. The IAMI is a 20-item self-report measure and is scored on a Likert-type scale, ranging from 0 (never) to 4 (once every hour or more). It is comprised of two subscales: frequency of future involuntary events and frequency of past involuntary events. Higher scores represent higher subscale levels of involuntary memory and thoughts.
Measured: Data will be collected at the baseline and immediately after the intervention.
Voluntary Control Questions (VCQ)
Measurement of the frequency of voluntary autobiographical memories and future thoughts. The VCQ is a 10-item self-report measure and is scored on a Likert-type scale, ranging from 0 (never) to 4 (once every hour or more). It is comprised of two subscales: frequency of future voluntary events and frequency of past voluntary events. Higher scores represent higher subscale levels of voluntary memory and thoughts.
Measured: Data will be collected at the baseline and immediately after the intervention.
Cognitive Biases Questionnaire for Psychosis (CBQp)
Assessment of bias related to psychosis. The CBQp consist of 30 descriptions of everyday situations related to anomalous perceptions or threatening events. Each group of statements covers five cognitive biases: intentionalising, catastrophising, dichotomous thinking, jumping to conclusions and emotional reasoning. Higher scores represent higher level of cognitive biases.
Measured: Data will be collected at the baseline and immediately after the intervention.
Brief Core Schema Scales
Measurement of schemas. The BCSS have 24 items concerning beliefs about the self and others that are assessed on a five-point rating scale (0-4). Four scores are obtained: negative-self, positive- self, negative-others and positive-others. Higher scores indicate a greater endorsement of a schema.
Measured: Data will be collected at the baseline and immediately after the intervention.
Brief Experiential Avoidance Questionnaire Questionnaire
Measurement of the functional process to connect with emotions. The BEAQ is comprised of 15 items, with each item being rated from 1 (Strongly disagree) to 6 (Strongly agree). The total score ranges from 15 to 90, with higher scores indicating more experiential avoidance.
Measured: Data will be collected at the baseline and immediately after the intervention.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Apr 2022
- Study start1 Jun 2021
- Primary completion28 Feb 2022
- Study completion28 Feb 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for SchizophreniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Device feasibility
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- A prospective non-randomised feasibility trial
- Masking
- None (open label)
- Enrolment
- 7 participants (actual)
Sponsor and investigators
- Lead sponsor
- Grupo Pulso
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Hospital de Sant Pau, Nurogames GmbH, Fundació Tic Salut i Social
- Responsible party
- Sponsor
- Investigators
- Iluminada Corripio, PhD, Principal investigator, Hospital de Sant Pau
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05345977
- Sponsor's protocol ID
- 12470-2
- Status last verified
- Apr 2024
- First submitted
- 16 Mar 2022
- Last updated
- 5 Apr 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Grasa E, Forment A, Alonso-Solis A, Ramalho L, Roldan A, Pousa E, Ausso S, Berdun J, Genova Tesoro A, Escudero J, Corripio I. Defining the Patient Journey and Identifying Digital Health Solutions in Treatment-Resistant Schizophrenia. Actas Esp Psiquiatr. 2025 Dec;53(6):1208-1222. doi: 10.62641/aep.v53i6.1959.
PubMed 41437755
Study at a glance
From the registry record, last updated by the sponsor on 5 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- eMotiph: Smart and Innovative E-mental Health Solution to Manage Patients With Schizophrenia
- ClinicalTrials.gov ID
- NCT05345977
- Acronym / sponsor ID
- 12470-2
- Conditions
- Schizophrenia
- Keywords
- mHealth, Treatment resistent schizophrenia
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 7 participants (actual)
- Lead sponsor
- Grupo PulsoIndustry (pharma, biotech, devices)
- Collaborators
- Hospital de Sant Pau, Nurogames GmbH, Fundació Tic Salut i Social
- Study start
- 1 Jun 2021 (actual)
- Primary completion
- 28 Feb 2022 (actual)
- Study completion
- 28 Feb 2022 (actual)
- First posted
- 26 Apr 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Although the main objective of current schizophrenia intervention programs is the reduction of symptoms, its rates are around 36%, and recovery rates are 16.5%. Between 30 and 50% of people with schizophrenia obtain little benefit with conventional therapy. They are considered resistant to treatment. Therefore, the development of innovative evidence-based interventions adjunctive to pharmacological and psychological treatment are necessary for improving results in patients with treatment-resistant schizophrenia (TRS). Studies with digital solutions have shown feasibility, acceptability and even preliminary efficacy data. But no earlier published study has focused on TRS.
The eMOTIPH is an innovative solution addressed to TRS and born from the outcomes of the previous study eMOTIPH Part 1 (study of beliefs, needs, and limitations associated with current intervention in TRS patients).
Detailed description
A prospective non-randomised feasibility trial will be performed. People with a diagnosis of treatment-resistant schizophrenia and their informal caregivers will test the digital mental health solution eMOTIPH for 6 months. Psychiatric treatment and psychological intervention (based on the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders; Farchione et al., 2012) will be delivered to patients.
The aim of the study is to evaluate the feasibility, acceptability, usability, satisfaction and perceived quality of life after using the eMOTIPH digital solution.
Study design
- Primary purpose
- Device feasibility
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- A prospective non-randomised feasibility trial
| Arm | Type | Receives |
|---|---|---|
| Unified Protocol | Experimental | Device: eMotiphThe psychotherapy Unified Protocol for Transdiagnostic Treatment of Emotional Disorders. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Age between 18-55 years old.
- Diagnosis of schizophrenia following the Diagnostic and Statistical Manual of Mental Disorders-5 criteria.
- Meet criteria for treatment-resistant schizophrenia.
- Used to information and communication technology and with the physical capability to use them.
Key exclusion criteria (4 listed)
- Meet criteria for remission according to the Remission of Schizophrenia Working Group (Andreasen et al., 2005).
- The presence of delusions mainly related to their therapists or with new technologies.
- Hearing, vision or motor impairment that makes it impossible to operate a smartphone.
- Intellectual Developmental Disability.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| eMotiphMobile application for patients with schizophrenia. | Device | Unified Protocol |
Primary outcome
Technology Acceptance Model Scale (TAM)
Time frame: Data will be collected immediately after the intervention.
Degree of acceptance of the digital solution and the intervention delivered. The scale provides scores in 8 dimensions: Perceived Usefulness (score ranges from 5 to 35), Perceived Ease of Use (score ranges from 6 to 42), Attitude (score ranges from 2 to 14), Facilitators (score ranges from 4 to 28), Barriers (score ranges from 2 to 14), Subjective Norm (score ranges from 3 to 21), Intention to Use (score ranges from 1 to 7) and Habits (score ranges from 2 to 14). As much the response trend is located in the positive pole for most of the items, higher acceptability.
User experience questionnaire
Time frame: Data will be collected immediately after the intervention
A questionnaire ad hoc will be created where the degree of usability and lived experience after using the digital solution will be measured. This scale has not cut off points. Higher values mean higher usability.
Client Satisfaction Questionnaire (CSQ-8)
Time frame: Data will be collected immediately after the intervention
The opinions and conclusions about the digital solution delivered will be asked. The scale has not cut off points. Higher values mean higher satisfaction.
27 secondary outcomes
Positive and Negative Syndrome Scale (PANSS)
Time frame: Change from Baseline Positive and Negative Syndrome Scale at 6 months.
Calgary Depresion Scale for Schizophrenia (CDS)
Time frame: Change from Baseline Calgary Depresion Scale for Schizophrenia at 6 months.
Beck Anxiety Inventory (BAI)
Time frame: Change from Baseline Beck Anxiety Inventory at 6 months.
Clinical Global Impression (CGI)
Time frame: Change from Baseline Clinical Global Impression at 6 months.
NEO Five-Factor Inventory
Time frame: Change from Baseline NEO Five-Factor Inventory at 6 months.
Toronto Alexithymia Scale (TAS)
Time frame: Change from Baseline Toronto Alexithymia Scale at 6 months.
Global Assessment Functioning (GAF)
Time frame: Change from Baseline Global Assessment Functioning at 6 months.
Personal and Social Performance scale (PSP)
Time frame: Change from Baseline Personal and Social Performance scale at 6 months.
EuroQuol-VAS (EQ-VAS)
Time frame: Change from Baseline EQ-VAS at 6 months.
Boston University Empowerment Scale (BUES)
Time frame: Change from Baseline Boston University Empowerment Scale at 6 months.
Questionnaire about the Process of Recovery
Time frame: Change from Baseline Questionnaire about the Process of Recovery at 6 months.
Visual numerical scale of recovery
Time frame: Change from Baseline Visual numerical scale of recovery at 6 months.
Psychotic Symptom Rating Scales-hallucinations (PSYRATS-H)
Time frame: Change from Baseline Psychotic Symptom Rating Scales at 6 months.
Peters Delusions Inventory (PDI)
Time frame: Change from Baseline Peters Delusions Inventory at 6 months.
Scale Unawareness of Mental Disorders (SUMD)
Time frame: Change from Baseline Scale Unawareness of Mental Disorders at 6 months.
Beck Cognitive Insight Scale
Time frame: Change from Baseline Beck Cognitive Insight Scale at 6 months.
Overall Depression Severity and Impairment Scale (ODSIS)
Time frame: Data will be collected at baseline, throughout the Unified Protocol sessions and immediately after the intervention.
Overall Anxiety Severity and Impairment Scale (OASIS)
Time frame: Data will be collected at baseline, throughout the Unified Protocol sessions and immediately after the intervention.
Baron Cohen's Face Test
Time frame: Data will be collected at the baseline and immediately after the intervention.
Emotion Regulation Questionnaire (ERQ)
Time frame: Data will be collected at the baseline and immediately after the intervention.
Difficulties in Emotion Regulation Scale (DERS)
Time frame: Data will be collected at the baseline and immediately after the intervention.
Five Facet Mindfulness Questionnaire (FFMQ)
Time frame: Data will be collected at the baseline and immediately after the intervention.
Involuntary Autobiographical Memory Inventory (IAMI)
Time frame: Data will be collected at the baseline and immediately after the intervention.
Voluntary Control Questions (VCQ)
Time frame: Data will be collected at the baseline and immediately after the intervention.
Cognitive Biases Questionnaire for Psychosis (CBQp)
Time frame: Data will be collected at the baseline and immediately after the intervention.
Brief Core Schema Scales
Time frame: Data will be collected at the baseline and immediately after the intervention.
Brief Experiential Avoidance Questionnaire Questionnaire
Time frame: Data will be collected at the baseline and immediately after the intervention.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Apr 2024.
- Derived from this study: PubMed 41437755Grasa E, Forment A, Alonso-Solis A, Ramalho L, Roldan A, Pousa E, Ausso S, Berdun J, Genova Tesoro A, Escudero J, Corripio I. Defining the Patient Journey and Identifying Digital Health Solutions in Treatment-Resistant Schizophrenia. Actas Esp Psiquiatr. 2025 Dec;53(6):1208-1222. doi: 10.62641/aep.v53i6.1959.
Related trials for Schizophrenia
Recruiting
Magnetic Seizure Therapy for Schizophrenia - Trial
Treatment Resistant Schizophrenia, Schizophrenia
RecruitingPhase 2
Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
Schizophrenia
RecruitingPhase 3
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
Schizophrenia
Recruiting
Developing Biomarker-Supported Schizophrenia Spectrum Disorder (SSD) Prevention
Schizophrenia Spectrum Disorders (SSD)
Recruiting
Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations
Auditory Verbal Hallucinations, Schizophrenia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Iluminada Corripio, PhD principal investigator
Hospital de Sant Pau
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing eMotiph in people with Schizophrenia, run by Grupo Pulso at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Technology Acceptance Model Scale (TAM) (time frame: Data will be collected immediately after the intervention.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05345977, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Apr 2024; AzTrials last refreshed its copy on 2 Nov 2026.